Protective effects of valsartan and benazepril combined with atorvastatin on cardiorenal syndrome in rats

European Review for Medical and Pharmacological Sciences

Volumn 19, Issue 5, 2015, Pages 759-766

  Tang, S Y ^a   Peng, D F ^a   Hu, Y J ^a   Chen, J ^a  

^a Puai Hospital   (China)

Author keywords

Alsartan; Atorvastatin; Benazepril; Cardiorenal syndrome; Rat

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ATORVASTATIN; BENAZEPRIL; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CHOLESTEROL; CREATININE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEIN; TRIACYLGLYCEROL; VALSARTAN; ANGIOTENSIN II; BENZAZEPINE DERIVATIVE; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE; TETRAZOLE DERIVATIVE; VALINE;

ALDOSTERONE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CARDIORENAL SYNDROME; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE PRESSURE; HEART PROTECTION; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HEART WEIGHT; LIPID BLOOD LEVEL; MALE; NONHUMAN; PROTEIN URINE LEVEL; RAT; RENAL PROTECTION; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; CARDIO-RENAL SYNDROME; CASE CONTROL STUDY; DRUG POTENTIATION; METABOLISM; PROTEINURIA; RANDOMIZATION; SPRAGUE DAWLEY RAT; URINE;

ANGIOTENSIN II; ANIMALS; BENZAZEPINES; C-REACTIVE PROTEIN; CARDIO-RENAL SYNDROME; CASE-CONTROL STUDIES; DRUG SYNERGISM; HEPTANOIC ACIDS; LIPIDS; MALE; NATRIURETIC PEPTIDE, BRAIN; PROTEINURIA; PYRROLES; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; TETRAZOLES; VALINE;

EID: 84942118558     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. BONGARTZ LG, BRAAM B, VERHAAR MC, CRAMER MJ, GOLDSCHMEDING R, GAILLARD CA, DOEVENDANS PA, JOLES JA. Transient nitric oxide reduction induces permanent cardiac systolic dysfunction and worsens kidney damage in rats with chronic kidney disease. Am J Physiol Regul Integr Comp Physiol 2010;298:R815-23.
2. RONCO C, MCCULLOUGH P, ANKER SD, ANAND I, ASPROMONTE N, BAGSHAW SM, BELLOMO R, BERL T, BOBEK I, CRUZ DN, DALIENTO L, DAVENPORT A, HAAPIO M, HILLEGE H, HOUSE AA, KATZ N, MAISEL A, MANKAD S, ZANCO P, MEBAZAA A, PALAZZUOLI A, RONCO F, SHAW A, SHEINFELD G, SONI S, VESCOVO G, ZAMPERETTI N, PONIKOWSKI P. Cardio-renal syndromes: report from he consensus conference of the acute dialysis quality initiative. Eur Heart J 2010;31:703-711.
3. PENG DF, TANG SY, HU YJ, CHEN J, YANG L. Pathophysiological model of chronic heart failure complicated with renal failure caused by three-quarter nephrectomy and subcutaneous injection of isoprenaline. Exp Ther Med 2013;5:835-839.
4. GRANGER CB, MCMURRAY JJV, YUSUF S, HELD P, MICHELSON EL, OLOFSSON B, OSTERGREN J, PFEFFER MA, SWEDBERG K. Effects of candesartan in patients with chronic heart failure and reduced leftventricularsystolic function intolerant to angioten sinc-onverting-enzyme inhibitors: the CHARM-alternative Trial. Lancet 2003;362:772-776.
5. ABRAHAM I, MACDONALD K, HERMANS C, AERTS A, LEE C, BRIÉ H, VANCAYZEELE S. Real-world effectiveness of valsartan on hypertension and total cardiovascular risk: review and implications of a translateonal research program. Vasc Health Risk Manag 2011;7:209-235.
6. JUN S, TAKAHISA S, MASAHIRO K, YAMADA H, MATSUBARA H. Cardio-cerebrovascular protective effects of valsartan in high-risk hypertensive patients with coronary artery disease (from the Kyoto Heart Study). Am J Cardiol 2012;109:1308-1314.
7. RAMASUBBU K, ESTEP J, WHITE DL, DESWAL A, MANN DL. Experimental and clinical basis for the us of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol 2008;51:415-426.
8. GISSI-HF INVESTIGATORS, TAVAZZI L, MAGGIONI AP, MARCHIOLI R, BARLERA S, FRANZOSI MG, LATINI R, LUCCI D, NICOLOSI GL, PORCU M, TOGNONI G. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1231-1239.
9. STRIPPOLI GF, NAVANEETHAN SD, JOHNSON DW, PERKOVIC V, PELLEGRINI F, NICOLUCCI A, CRAIG JC. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. Br Med J 2008;336:645-651.
10. FUJII M, INOGUCHI T, MAEDA Y, SASAKI S, SAWADA F, SAITO R, KOBAYASHI K, SUMIMOTO H, TAKAYANAGI R. Pitavastatin ameliorates albuminuria and renal mesangial expansion by downregulating NOX4 in db/db mice. Kidney Int 2007;4:473-480.
11. HORIUCHI M, CUI TX, LI Z, LI JM, NAKAGAMI H, IWAI M. Fluvastatin enhances the inhibitory effects of a selective angiotensin II type1 receptor blocker, valsartan, on vascularneointimal formation. Circulation 2003;107:106-112.
12. BAYORH MA, LAYAS MF, MANN G, FEUERSTEIN GZ, EATMAN D. The effect of diet on simvastatin and losartan enhancement endothelial function. Clin Exp Hypertens 2007;29:311-325.
13. SMINK PA, LAMBERS HJ, GANSEVOORT RT, DE JONG PE, HILLEGE HL, BAKKER SJ, DE ZEEUW D. Albuminuria, estimated GFR, traditional risk factors and incident cardiovascular disease: the PREVEND (Prevention of Renal and Vascular End stage Disease) Study. Am J Kidney Dis 2012;60:804-811.
14. MASSON S, LATINI R, ANAND LS, BARLERA S, ANGELICI L, VAGO T, TOGNONI G, COHN JN. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol 2008;52:997-1003.
15. LIPINSKI MJ, CAUTHEN CA, BIONDI-ZOCCAI GG, ABBATE A, VRTOVEC B, KHAN BV, VETROVEC GW. Meta-analysis of randomized controlled trials of statins versus placebo in patients with heart failure. Am J Cardiol 2009;104:1708-1716.
16. BAIGENT C, LANDRAY MJ, REITH C, EMBERSON J, WHEELER DC, TOMSON C, WANNER C, KRANE V, CASS A, CRAIG J, NEAL B, JIANG L, HOOI LS, LEVIN A, AGODOA L, GAZIANO M, KASISKE B, WALKER R, MASSY ZA, FELDTRASMUSSEN B, KRAIRITTICHAI U, OPHASCHAROENSUK V, FELLSTRÖM B, HOLDAAS H, TESAR V, WIECEK A, GROBBEE D, DE ZEEUW D, GRÖNHAGEN-RISKA C, DASGUPTA T, LEWIS D, HERRINGTON W, MAFHAM M, MAJONI W, WALLENDSZUS K, GRIMM R, PEDERSEN T, TOBERT J, ARMITAGE J, BAXTER A, BRAY C, CHEN Y, CHEN Z, HILL M, KNOTT C, PARISH S, SIMPSON D, SLEIGHT P, YOUNG A, COLLINS R. The effectsof lowering LDL cholesterol with simvastatin plus ezetimibe inpatients with chronic kidney disease, study of heart and renal protection: a randomized placebo-controlled trial. Lancet 2011;377:2181-2192.
17. SHARP COLLABORATIVE GROUP: STUDY OF HEART AND RENAL PROTECTION (SHARP). Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9, 438 patients with chronic kidney disease. Am Heart J 2010;160:785-794.
18. LIU M, WANG F, WANG Y, JIN R. Atorvastatin improves endothelial function and cardiac performance in patients with dilated cardiomyopathy: the role of inflamm ation. Cardiovasc Drugs Ther 2009;23:369-376.
19. TOUSOULIS D, CHARAKIDA M, STEFANADI E, SIASOS G, LATSIOS G, STEFANADIS C. Statins in heart failure. Beyond the lipid lowering effect. Int J Cardiol 2007;115:144-1450.
20. BU DX, TARRIO M, GRABIE N, ZHANG Y, YAMAZAKI H, STAVRAKIS G, MAGANTO-GARCIA E, PEPPER-CUNNINGHAM Z, JAROLIM P, AIKAWA M, GARCÍA-CARDEÑA G, LICHTMAN AH. Statin-induced Kruppel-like factor 2 expression in human and mouse T cells reduces inflammatory and pathogenic responses. J Clin Invest 2010;120:1961-1970.
21. TOUSOULIS D, ANDREOU I, TSIATAS M, MILIOU A, TENTOLOURIS C, SIASOS G, PAPAGEORGIOU N, PAPADIMITRIOU CA, DIMOPOULOS MA, STEFANADIS C. Effects of rosuvastatin and allopurinol on circulating endothelial progenitor cells in patients with congestive heart failure: the impact of inflammatory process and oxidative stress. Atherosclerosis 2011;214:151-157.
22. CZEWSKI MM, CZEWSKA JM, DUDA M. Hypercholesterolaemia exacerbates ventricularremodelling after myocardial infarction in the ratrole of angiotensin II type 1 receptors. Br J Pharmacol 2008;154:1640-1648.
23. BLANCO S, VAQUERO M, GÓMEZ-GUERRERO C, LÓPEZ D, EGIDO J, ROMERO R. Potential role of angiotensinconverting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension. Am J Hypertens 2005;18(4 Pt 1):557-565.